ZFIN Fish: fgf8a^ti282a/+

ZFIN ID: ZDB-FISH-150901-3034

ZFIN ID: ZDB-FISH-150901-3034

Fish name:	fgf8a^ti282a/+
Genotype:	fgf8a^ti282a/+
Targeting Reagent:	none

HUMAN DISEASE MODELED by fgf8a^ti282a/+
No data available

GENE EXPRESSION
Gene expression in fgf8a^ti282a/+

RNA expression

Expressed Gene	Structure	Conditions	Figures
dlx3b	otic placode	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
egr2b	presumptive rhombomere 3 presumptive rhombomere 5	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
foxi1	neurogenic placode	standard conditions	Fig. 5 from Nechiporuk et al., 2007
	otic placode	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
fsta	paraxial mesoderm	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
isl1	trigeminal placode	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
pax2a	glossopharyngeal placode midbrain hindbrain boundary otic placode otic vesicle vagal ganglion 1 vagal ganglion 2 vagal ganglion 3 vagal ganglion 4	standard conditions	Fig. 5 from Nechiporuk et al., 2007
	otic placode	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
pax8	otic placode paraxial mesoderm	chemical treatment: SB 431542	Fig. 4 , Fig. 5 from Kwon et al., 2009
shha	(not) axial mesoderm	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009

Protein expression No data available

Reporter gene expression No data available

PHENOTYPE
Phenotype in fgf8a^ti282a/+

Phenotype	Conditions	Figures
chondrocranium bilateral symmetry, abnormal	standard conditions	Fig. 2 from Albertson et al., 2007
embryonic viscerocranium morphogenesis process quality, normal	control	Fig. 9 from Lovely et al., 2016
embryonic viscerocranium morphogenesis process quality, normal	chemical treatment: dorsomorphin	Fig. 9 from Lovely et al., 2016
opercle bilateral symmetry, abnormal	standard conditions	Fig. 3 from Albertson et al., 2007
opercle malformed, abnormal	standard conditions	Fig. 3 from Albertson et al., 2007
otic placode decreased amount, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic placode malformed, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic placode mislocalised medially, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic placode formation process quality, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic placode formation process quality, abnormal	chemical treatment: SB 431542	Fig. 5 from Kwon et al., 2009
otic vesicle decreased amount, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic vesicle increased size, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic vesicle malformed, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
otic vesicle mislocalised medially, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
paraxial mesoderm mislocalised medially, abnormal	chemical treatment: SB 431542	Fig. 4 from Kwon et al., 2009
paraxial mesodermal cell fate specification process quality, abnormal	chemical treatment: SB 431542	Fig. 5 from Kwon et al., 2009
regulation of bone remodeling occurrence, abnormal	standard conditions	Fig. 5 from Albertson et al., 2007
ventral mandibular arch bilateral symmetry, abnormal	standard conditions	Fig. 2 from Albertson et al., 2007
ventral mandibular arch malformed, abnormal	standard conditions	Fig. 2 , Fig. 5 from Albertson et al., 2007

CITATIONS (8)